PolyPid Ltd.

PolyPid Ltd. (PYPD) priced its initial public offering on Jun 29, 2020 at $16.00 per share, raising $60M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $272.7M. Barclays was lead-left underwriter, joined by BMO Capital Markets, Raymond James and A.G.P.. Cooley advised the company and Latham & Watkins advised the underwriters.

PolyPid Ltd. is a Phase 3 clinical-stage biopharmaceutical company developing locally administered, prolonged-release therapeutics using its PLEX polymer-lipid technology. Its lead candidate, D-PLEX 100, is in a Phase 3 trial for preventing sternal surgical site infections.

Status

IPO

Ticker

PYPD

Exchange

Nasdaq Global Market

Priced

Jun 29, 2020

IPO price

$16.00

Raised

$60M

Market cap at IPO price

$272.7M

First filed

Oct 14, 2014

Underwriters

Barclays, BMO Capital Markets, Raymond James and A.G.P.

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Healthcare

Country / state

Israel

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.